Article info
PDFReview
UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines
- Correspondence to Dr Ruth Dobson, Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London E1 2AT, UK; ruth.dobson{at}qmul.ac.uk
Citation
UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines
Publication history
- Received July 26, 2018
- Revised September 11, 2018
- Accepted September 30, 2018
- First published January 5, 2019.
Online issue publication
March 14, 2019
Article Versions
- Previous version (5 January 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Disease-modifying therapies for multiple sclerosis
- Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
- Disease modification in multiple sclerosis: an update
- Update on disease-modifying therapies for multiple sclerosis
- Disease modifying therapies for relapsing multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study